NO770898L - Fremgangsm}te til stabilisering av erythrocyter - Google Patents

Fremgangsm}te til stabilisering av erythrocyter

Info

Publication number: NO770898L
Authority: NO; Norway
Prior art keywords: erythrocytes; glyoxal; treated; formaldehyde; treatment
Prior art date: 1976-03-16

Application number

NO770898A

Other languages

English (en)

Norwegian (no)

Inventor

Frank Falkowski

Leonard Wilson

Original Assignee

Ortho Diagnostics

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-03-16

Filing date

1977-03-14

Publication date

1977-09-19

1977-03-14 Application filed by Ortho Diagnostics filed Critical Ortho Diagnostics

1977-09-19 Publication of NO770898L publication Critical patent/NO770898L/no

Links

238000000034 method Methods 0.000 title claims description 34
230000006641 stabilisation Effects 0.000 title description 4
238000011105 stabilization Methods 0.000 title description 4
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 68
210000003743 erythrocyte Anatomy 0.000 claims description 64
210000004027 cell Anatomy 0.000 claims description 57
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 47
229940015043 glyoxal Drugs 0.000 claims description 36
239000000427 antigen Substances 0.000 claims description 19
102000036639 antigens Human genes 0.000 claims description 19
108091007433 antigens Proteins 0.000 claims description 19
238000001514 detection method Methods 0.000 claims description 11
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 11
239000001509 sodium citrate Substances 0.000 claims description 11
239000000243 solution Substances 0.000 claims description 10
239000012736 aqueous medium Substances 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 6
230000035931 haemagglutination Effects 0.000 claims description 5
239000000725 suspension Substances 0.000 claims description 5
208000006454 hepatitis Diseases 0.000 claims description 3
231100000283 hepatitis Toxicity 0.000 claims description 3
230000000087 stabilizing effect Effects 0.000 claims description 2
239000007900 aqueous suspension Substances 0.000 claims 3
239000012431 aqueous reaction media Substances 0.000 claims 1
238000005534 hematocrit Methods 0.000 description 21
238000006243 chemical reaction Methods 0.000 description 17
210000004369 blood Anatomy 0.000 description 11
239000008280 blood Substances 0.000 description 11
239000000463 material Substances 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
150000001299 aldehydes Chemical class 0.000 description 10
239000000523 sample Substances 0.000 description 10
AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 8
239000002609 medium Substances 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
230000004520 agglutination Effects 0.000 description 6
239000000178 monomer Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
208000002672 hepatitis B Diseases 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
206010018910 Haemolysis Diseases 0.000 description 3
241001494479 Pecora Species 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000000834 fixative Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000008588 hemolysis Effects 0.000 description 3
239000006194 liquid suspension Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000013638 trimer Substances 0.000 description 3
IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
241000282412 Homo Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010029719 Nonspecific reaction Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
241000286209 Phasianidae Species 0.000 description 2
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
238000011005 laboratory method Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
101100459439 Caenorhabditis elegans nac-2 gene Proteins 0.000 description 1
102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
230000000254 damaging effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000029142 excretion Effects 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000005187 foaming Methods 0.000 description 1
229960004279 formaldehyde Drugs 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960000587 glutaral Drugs 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229940084986 human chorionic gonadotropin Drugs 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000005499 meniscus Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
- G01N33/555—Red blood cell
- G01N33/556—Fixed or stabilised red blood cell
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03G—ELECTROGRAPHY; ELECTROPHOTOGRAPHY; MAGNETOGRAPHY
- G03G15/00—Apparatus for electrographic processes using a charge pattern
- G03G15/20—Apparatus for electrographic processes using a charge pattern for fixing, e.g. by using heat
- G03G15/2092—Apparatus for electrographic processes using a charge pattern for fixing, e.g. by using heat using pressure only
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03G—ELECTROGRAPHY; ELECTROPHOTOGRAPHY; MAGNETOGRAPHY
- G03G9/00—Developers
- G03G9/08—Developers with toner particles
- G03G9/087—Binders for toner particles
- G03G9/08702—Binders for toner particles comprising macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
- G03G9/08704—Polyalkenes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/826—Additives, e.g. buffers, diluents, preservatives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Cell Biology (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
General Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Biotechnology (AREA)
Spectroscopy & Molecular Physics (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO770898A 1976-03-16 1977-03-14 Fremgangsm}te til stabilisering av erythrocyter NO770898L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US05/667,316 US4136161A (en)	1976-03-16	1976-03-16	Stabilized erythrocytes and methods therefor

Publications (1)

Publication Number	Publication Date
NO770898L true NO770898L (no)	1977-09-19

Family

ID=24677729

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO770898A NO770898L (no)	1976-03-16	1977-03-14	Fremgangsm}te til stabilisering av erythrocyter

Country Status (15)

Country	Link
US (1)	US4136161A (de)
AT (1)	AT357689B (de)
AU (2)	AU2323577A (de)
BE (1)	BE852482A (de)
CA (1)	CA1090700A (de)
DE (1)	DE2711489A1 (de)
DK (1)	DK110777A (de)
ES (1)	ES456913A1 (de)
FR (1)	FR2344842A1 (de)
IL (1)	IL51662A (de)
IT (1)	IT1083729B (de)
NL (1)	NL7702861A (de)
NO (1)	NO770898L (de)
SE (1)	SE7702917L (de)
ZA (1)	ZA771553B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2828235C2 (de) *	1978-06-28	1980-04-17	Kernforschungsanlage Juelich Gmbh, 5170 Juelich	Verfahren und Adsorptionsmittel zur Isolierung und Reindarstellung von Enzymen aus einer Roh-Enzym-Lösung
US4202665A (en) *	1978-11-06	1980-05-13	Albert Einstein College Of Medicine Of Yeshiva University A Division Of Yeshiva University	Detection of hepatitis B surface antigen
JPS566161A (en) *	1979-06-28	1981-01-22	Seikagaku Kogyo Co Ltd	Erythropoietin sensitized latex
JPS59192961A (ja) *	1983-04-15	1984-11-01	Green Cross Corp:The	血液凝固第「じ」因子測定用試薬
US4939096A (en) *	1986-09-10	1990-07-03	Idexx, Corp.	Method and apparatus for assaying whole blood
US5759774A (en) *	1988-05-18	1998-06-02	Cobe Laboratories, Inc.	Method of detecting circulating antibody types using dried or lyophilized cells
US5008202A (en) *	1988-11-29	1991-04-16	Sequoia Turner Corporation	Blood diluent for red blood cell analysis
WO1992006696A1 (fr) *	1990-10-11	1992-04-30	Innovatsionno-Venchurnaya Firma 'chernovitsky Gorodskoi Tsentr Nauchno-Tekhnicheskogo Tvorchestva Molodezhi 'ort'	Procede d'obtention d'une preparation bioactive a partir du sang
EP0627879A1 (de) *	1991-09-20	1994-12-14	CAMIENER, Gerald, W.	Verfahren und zusammensetzungen mit einer aldehydstabilisierenden lösung
US5998483A (en) *	1991-09-20	1999-12-07	Camiener; Gerald W.	Glyoxal-containing preservative compositions
US5401625A (en) *	1993-06-24	1995-03-28	E. K. Industries, Inc.	Histological composition for light microscopy
JP6300352B2 (ja) *	2014-03-31	2018-03-28	シーシーアイ株式会社	中性脂肪濃度測定用の標準物質組成物およびその製造方法
JP2022547295A (ja) *	2019-09-05	2022-11-11	ヘマネクストインコーポレイテッド	一酸化炭素を使用した試薬赤血球の貯蔵のための方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL126572C (de) *	1966-03-24
GB1244344A (en) *	1967-11-13	1971-08-25	Abbott Lab	Hemagglutination testing procedure employing stabilized and potentiated erythrocytes and a method for their preparation
US3553310A (en) *	1967-12-28	1971-01-05	Miles Lab	Immunologically reactive particles
US3708572A (en) *	1969-03-26	1973-01-02	Baxter Laboratories Inc	Infectious mononucleosis diagnostic reagent and method
JPS5010374B1 (de) *	1969-11-10	1975-04-21
GB1392181A (en) *	1971-04-16	1975-04-30	Rech Et Dapplications Soc Gen	Fixation of nitrogenous materials

1976
- 1976-03-16 US US05/667,316 patent/US4136161A/en not_active Expired - Lifetime
1977
- 1977-03-04 CA CA273,254A patent/CA1090700A/en not_active Expired
- 1977-03-14 DK DK110777A patent/DK110777A/da not_active Application Discontinuation
- 1977-03-14 NO NO770898A patent/NO770898L/no unknown
- 1977-03-14 IT IT48458/77A patent/IT1083729B/it active
- 1977-03-15 FR FR7707676A patent/FR2344842A1/fr active Granted
- 1977-03-15 AU AU23235/77A patent/AU2323577A/en not_active Expired
- 1977-03-15 BE BE175811A patent/BE852482A/xx unknown
- 1977-03-15 AT AT175577A patent/AT357689B/de not_active IP Right Cessation
- 1977-03-15 ZA ZA00771553A patent/ZA771553B/xx unknown
- 1977-03-15 AU AU26235/77A patent/AU517510B2/en not_active Expired
- 1977-03-15 IL IL51662A patent/IL51662A/xx unknown
- 1977-03-15 SE SE7702917A patent/SE7702917L/xx unknown
- 1977-03-16 DE DE19772711489 patent/DE2711489A1/de not_active Withdrawn
- 1977-03-16 ES ES456913A patent/ES456913A1/es not_active Expired
- 1977-03-16 NL NL7702861A patent/NL7702861A/xx not_active Application Discontinuation

Also Published As

Publication number	Publication date
FR2344842B1 (de)	1981-01-02
US4136161A (en)	1979-01-23
ATA175577A (de)	1979-12-15
BE852482A (fr)	1977-09-15
AT357689B (de)	1980-07-25
AU2323577A (en)	1978-09-21
ES456913A1 (es)	1978-07-16
IL51662A0 (en)	1977-05-31
CA1090700A (en)	1980-12-02
DE2711489A1 (de)	1977-09-22
IL51662A (en)	1979-11-30
AU2623577A (en)	1979-01-04
SE7702917L (sv)	1977-09-17
FR2344842A1 (fr)	1977-10-14
AU517510B2 (en)	1981-08-06
DK110777A (da)	1977-09-17
ZA771553B (en)	1978-10-25
IT1083729B (it)	1985-05-25
NL7702861A (nl)	1977-09-20

Publication	Publication Date	Title
Parker et al.	2017	The direct antiglobulin test: indications, interpretation, and pitfalls
JP4673871B2 (ja)	2011-04-20	赤血球用懸濁媒体
US5489386A (en)	1996-02-06	Density gradient medium for the separation of cells
US6406915B2 (en)	2002-06-18	Hematology control and system for multi-parameter hematology measurements
NO770898L (no)	1977-09-19	Fremgangsm}te til stabilisering av erythrocyter
CA1113391A (en)	1981-12-01	Direct assay of free analyte
Eadie et al.	1955	The potential life span and ultimate survival of fresh red blood cells in normal healthy recipients as studied by simultaneous Cr 51 tagging and differential hemolysis
EP0161281A4 (de)	1987-04-28	Stabilisierung von indikatoren zum nachweis von enzymaktivität.
US4292038A (en)	1981-09-29	Formamide-containing latex agglutinating reagent for immunoassay
WO1981003225A1 (en)	1981-11-12	Antibody detection process and reagents therefor
US4311690A (en)	1982-01-19	Test set and method for the determination of free hormones
KR900002840B1 (ko)	1990-05-01	안정화된 효소 결합체 조성물
US6146901A (en)	2000-11-14	Composition for manipulating optical and electrical properties of particles to achieve target values for such properties and methods for using the composition
US6368785B1 (en)	2002-04-09	Anti-coagulation of blood, plasma or synovial fluid products using iso-citrate
KR890000393B1 (ko)	1989-03-16	비루스성 적혈구 응집 반응 시험용 조류(鳥類)고정 적혈구의 보존액
Green et al.	1953	A study of isotonic solutions for the erythrocytes of some marine teleosts and elasmobranchs
Herman et al.	1987	Th activation in congenital hypoplastic anemia
US7767465B2 (en)	2010-08-03	Reduction of platelet interference in plasma assay samples
Waddell	1956	Lysis of dog erythrocytes in mildly alkaline isotonic media
US3733398A (en)	1973-05-15	Determining and reversing anticomplementary activity in complement fixation test for australia antigen
Branum et al.	1988	Effect of two anticoagulants on leukocyte yield and function, and on lysosomal enzyme activity.
JPS60244861A (ja)	1985-12-04	溶血式測定方法及びそれに使用する試薬キツト
Higgins	1994	Blood transfusion: risks and benefits
Tucker et al.	1971	The M‐L blood group system and active potassium transport in sheep reticulocytes
Daniels et al.	1982	Effects of hydroxyethyl starch on erythrocyte typing and blood crossmatching